lunes, 17 de noviembre de 2014

Is it time for BRCA1/2 mutation screening in the general adult population?: impact of population characteristics : Genetics in Medicine : Nature Publishing Group

Is it time for BRCA1/2 mutation screening in the general adult population?: impact of population characteristics : Genetics in Medicine : Nature Publishing Group



Is it time for BRCA1/2 mutation screening in the general adult population?: impact of population characteristics

Genetics in Medicine
 
(2014)
 
doi:10.1038/gim.2014.167
Received
 
Accepted
 
Published online 

Abstract

Genet Med advance online publication 06 November 2014
View full text

References

  1. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci USA2014;111:14205–14210.
  2. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 2014;312:1091–1092.
  3. American Cancer Society. Cancer Facts and Figures 2014. Atlanta.http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed 2 October 2014.
  4. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med2005;143:355–361.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2014. Jenkintown, PA, 2014.
  6. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66–71.
  7. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–792.
  8. Wald N, Cuckle H. Reporting the assessment of screening and diagnostic tests. Br J Obstet Gynaecol 1989;96:389–396.
  9. Haddow JE, Palomaki GE. An introduction to assessing genomic screening and diagnostic tests. Nutr Today 2011;46:162–168.
  10. McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005;7:28–33.
  11. McClain MR, Nathanson KL, Palomaki GE, Haddow JE. An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genet Med 2005;7:34–39.
Download references

Author information

Affiliations

  1. Division of Medical Screening and Special Testing, Department of Pathology and Laboratory Medicine, Women & Infants Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA

    • Glenn E. Palomaki

Corresponding author

Correspondence to: 
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)